| 产品描述: | Adoprazine (SLV313) is a full 5-HT1A receptor agonist with a pEC50 of 9 at cloned h5-HT1A receptors. Adoprazine (SLV313) is a full D2 and D3 receptor antagonist with pA2s of 9.3 and 8.9 at hD2 and hD3 receptors, respectively. Adoprazine (SLV313) has the characteristics of atypical antipsychotics. |
| 靶点: |
5-HT1A Receptor:9 (pEC50);D2 Receptor:9.3 (pA2);D3 Receptor:8.9 (pA2);D4 Receptor:8.0 (pKi);5-HT7 Receptor:7.2 (pKi);5-HT1A Receptor;9.1 (pKi);D2 Receptor:8.4 (pKi);D3 Receptor:8.4 (pKi);Others |
| 体内研究: |
Adoprazine (SLV313) (0.1-10 mg/kg; p.o.; single) is sufficient to reduce extracellular 5-HT and increase dopamine levels in the nucleus accumbens in a dose- and time-dependent manner Animal Model: Male Wistar rats (275-350 g) Dosage: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg Administration: p.o.; single Result: Led to a dose- and time-dependent increase in extracellular levels of DA, DOPAC, and HVA. In contrast, led to a reduction in 5-HT levels and no change in 5-HIAA levels. |
| 参考文献: |
1. Andrew C McCreary, et al. SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsych 2. Liesbeth A Bruins Slot, et al. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol. 2006 Mar 18;534(1-3):63-70. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
-20℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.466 ml |
12.332 ml |
24.663 ml |
| 5 mM |
0.493 ml |
2.466 ml |
4.933 ml |
| 10 mM |
0.247 ml |
1.233 ml |
2.466 ml |
| 50 mM |
0.049 ml |
0.247 ml |
0.493 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |